Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cardio Vascular Disease, Acute Coronary Syndromes (ACS), Type 2 Diabetes, Pre Diabetes. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Qatar
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.
Detailed description
This study combines retrospective and prospective designs.
Retrospective:
We use past electronic medical records to identify participants and collect baseline information from their initial visit (using their code or health card number).
Prospective:
From that starting point, we follow the same participants forward in time, updating data every two years and recording new outcomes (mortality, cardiovascular events, rehospitalizations, treatment-related outcomes) at planned checkpoints (approximately 6 months, 1 year, and 2 years).
New eligible participants identified in later data extractions are added and followed in the same manner. Because we only observe and record participants existing records and outcomes without assigning interventions, the study is observational.
Primary outcome measures
- Incidence of 3-point Major Adverse Cardiovascular Events (MACE) in Acute Coronary Syndrome Patients [Time frame: 5 years]
- Incidences of 2-point Major Adverse Cardiovascular Events (MACE) in Heart Failure Patients [Time frame: 5 years]
Secondary outcome measures (9)
- Major Adverse Cardiovascular Events [Time frame: 5 years]
- Unstable angina requiring hospitalization [Time frame: 5 years]
- Arrhythmic events [Time frame: 5 years]
- Coronary revascularization [Time frame: 5 years]
- Post-Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG) complications (stent/graft thrombosis or repeat revascularization) [Time frame: 5 years]
- Development or progression of valvular heart disease (aortic or mitral stenosis/regurgitation) [Time frame: 5 years]
- New-onset diabetes mellitus [Time frame: 5 years]
- Change in glycated Hemoglobin A1c (HbA1c) [Time frame: 5 years]
- Newly diagnosed medical or surgical conditions not present at baseline [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Age ≥ 18
- Qatari and Arab participants
- Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)
- Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%
Exclusion criteria
- Non-Qatari or non-Arab participants
- Non-diabetic: HbA1C < 5.7%
- This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Qatar · 1 center
- Hamad Medical Corporation — Doha
Identifiers
NCT: NCT07515807 · 25-00019